Herbalife misses profit estimates, share price plunges

By Hank Schultz

- Last updated on GMT

Herbalife misses profit estimates, share price plunges
Herbalife's share price dropped sharply yesterday as the company reported second quarter earnings that missed analysts’ estimates.  Shares dropped 11% almost immediately on the news and declined further in early trading today, with a share price at the time of publication of $56.10, down from a high of $69.10 on Monday.

Herbalife reported a second-quarter profit of $119.5 million, or $1.31 a share, compared with a profit of $143.2 million, or $1.34 a share, for the year-earlier period. The company notched $1.3 billion in revenue, compared to $1.22 billion in the year-ago quarter. Adjusted profit was $1.55 a share. Analysts were expecting a profit of $1.56 a share on revenue of $1.36 billion.  It was the first time the company has missed Wall Street estimates in 21 consecutive quarters.

Among Herbalife’s issues are costs related to responding to the pressure brought to bear by activist investor Bill Ackman, who through his Pershing Square investment firm has taken a $1 billion short position on the company.  And the company is bearing costs related to investigations as well, CEO Michael Johnson said.

“Our confidence in the success of our products and sales methods is a catalyst for member engagement and activity and our strong financial performance. As you know, our company is a subject of an FTC inquiry. We are confident that there will be a successful conclusion that will keep Herbalife on the path to success for years to come,” Johnson said in an earnings call with analysts.

Herbalife is the world’s largest network marketing company devoted solely to nutritional products.  The comapny recorded $4.8 billion in net sales in 2013.

Related news

Show more

Related products

show more

Brand Owners – Are You Getting the Supplement You Want?

Brand Owners – Are You Getting the Supplement You Want?

Content provided by Gemini Pharmaceuticals, Inc | 01-Nov-2024 | White Paper

Often the balance of “best value” and “best price” walks Brand Owners into a maze, and no industry seems to exemplify that like dietary supplements! However,...

Explore the scientific foundations of Nextida™ GC

Explore the scientific foundations of Nextida™ GC

Content provided by Rousselot | 01-Nov-2024 | White Paper

The first commercialised ingredient in the Nextida platform, a range of specific collagen peptide compositions with targeted health benefits, Nextida™...

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd | 22-Oct-2024 | Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™...

Related suppliers

Follow us

Products

View more

Webinars